C4 Therapeutics, Inc. (CCCC)
$
1.99
-0.03 (-1.51%)
Key metrics
Financial statements
Free cash flow per share
-1.1365
Market cap
143.4 Million
Price to sales ratio
3.6054
Debt to equity
0.3298
Current ratio
5.6966
Income quality
0.7778
Average inventory
0
ROE
-0.4586
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutic candidates aimed at degrading disease-causing proteins for the treatment of cancer, neurodegenerative disorders, and other illnesses. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. With a revenue of $35,584,000.00 the company demonstrates its niche market focus and commitment to addressing unmet medical needs. The gross profit stands at $35,584,000.00 highlighting the company's profitability from core operations. Furthermore, the operating income ratio is -3.36 indicating the company's operational profitability margin. Additionally, the company earned an interest income of $14,429,000.00 showcasing its financial investments. Its lead product candidate, CFT7455, is an orally bioavailable MonoDAC degrader undergoing a Phase 1/2 trial, targeting IKZF1 and IKZF3 for treating multiple myeloma and non-Hodgkin lymphomas. C4 Therapeutics is also advancing other promising candidates, including CFT8634, CFT1946, and CFT8919, as well as earlier-stage programs targeting RET degraders for various cancers. The company benefits from strategic collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Calico Life Sciences LLC. Founded in 2015, C4 Therapeutics is headquartered in Watertown, Massachusetts. The stock is affordable at $1.99 making it suitable for budget-conscious investors. Moreover, the stock has a high average trading volume of 1,272,313.00 indicating strong liquidity and interest among traders. With a market capitalization of $141,304,129.00 the company is classified as a small-cap player, reflecting its growth potential within the industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, C4 Therapeutics belongs to the Healthcare sector, where it drives innovation and growth. The company’s ongoing development programs position it well to impact the treatment landscape significantly, aligning with its strategic goals in the biopharmaceutical arena.
Is C4 Therapeutics, Inc. (CCCC) a good investment?
Investing in C4 Therapeutics, Inc. (CCCC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is C4 Therapeutics, Inc. (CCCC)'s stock forecast?
Analysts predict C4 Therapeutics, Inc. stock to fluctuate between $1.09 (low) and $7.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is C4 Therapeutics, Inc.'s market capitalization?
As of 2025-07-10, C4 Therapeutics, Inc.'s market cap is $141,304,129, based on 71,007,100 outstanding shares.
How does C4 Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, C4 Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy C4 Therapeutics, Inc. (CCCC) stock?
To buy C4 Therapeutics, Inc. (CCCC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CCCC. Place an order (Market, Limit, etc.).
What is the best time to invest in C4 Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did C4 Therapeutics, Inc. perform in the last earnings report?
Revenue: $35,584,000 | EPS: -$1.52 | Growth: -43.07%.
Where can I find C4 Therapeutics, Inc.'s investor relations reports?
Visit https://www.c4therapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for C4 Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for C4 Therapeutics, Inc. stock?
All-time high: $51.21 (2021-09-23) | All-time low: $1.06 (2023-12-06).
What are the key trends affecting C4 Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
25 days ago
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.
zacks.com
2 months ago
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.
globenewswire.com
2 months ago
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level
zacks.com
4 months ago
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
4 months ago
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
4 months ago
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.
globenewswire.com
4 months ago
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026
zacks.com
5 months ago
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
globenewswire.com
5 months ago
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.
zacks.com
6 months ago
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
See all news
